|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.40 EUR | -0.68% |
|
+9.55% | +72.91% |
| 12-04 | Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug | MT |
| 12-04 | Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome | CI |
Published on 12/02/2025 at 05:37 pm EST
Health-care companies fell as traders rotated back into higher risk sectors.
Shares of Bayer surged after the U.S. Solicitor General supported the German chemical and drug maker's push for the Supreme Court to take up its Roundup weedkiller case.
In the last decade, Bayer has paid out about $10 billion to plaintiffs who have claimed that Roundup's main ingredient, glyphosate, caused their cancer.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
12-02-25 1736ET
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
